From a Cannabis CFO: Focused on the Cannabinoid Economy

At BTA Cannabis CPA Tax, we serve one lane — and we stay in it: cannabis, hemp, and the “Wonderful World of Cannabinoids.”

We’ve been approached by psilocybin startups, nonprofit retreats, and alternative therapy ventures. And while we respect the mission, we’ve made a deliberate decision:
We do not offer accounting, tax, or CFO services to psilocybin or psychedelics businesses.

Here’s why:

1. No License, No Infrastructure = No Engagement.

We work with state-licensed, tax-paying cannabis operators. That’s non-negotiable.

Psilocybin, even where decriminalized or legalized for therapeutic use, lacks the regulatory depth cannabis has achieved. Outside of Oregon and Colorado, there’s no viable commercial licensing pathway. No established tax compliance systems. No consistent banking access.

For example, Oregon began accepting psilocybin service center license applications in January 2023, with only a limited number of license types and operators active. Colorado is in the early stages of implementation under the Natural Medicine Health Act — but regulations and business licensing are still in flux.

As a CFO, I can’t build financial infrastructure on legal ambiguity. Our role is to support operators who are playing by the rules — and psilocybin just isn’t there yet at scale.

2. We’re Experts in Cannabis — Not Generalists in Plant Medicine.

Our firm was built for cannabis — and built by cannabis professionals.

We operate in the deep end of tax code and compliance: 280E strategy, inventory costing, METRC integration, CDTFA audits, and real-time advisory for licensed operators. This work demands precision, institutional knowledge, and constant adaptation to state and local changes.

Our tax and compliance services are designed specifically for cannabis and hemp operators navigating this unique regulatory landscape.

Psilocybin businesses, by contrast, lack a standardized regulatory framework. Outside a handful of state programs, there are no mature banking models, no industry-specific tax policies, and no uniform commercial oversight. It’s not about 280E — both cannabis and psilocybin fall under that. It’s about whether the basic bones of a compliant business even exist yet.

We’re not anti-psychedelics. But we’re not in the business of “alternative wellness” as a catch-all. We serve licensed, tax-paying cannabis, hemp, and cannabinoid businesses — and that’s where we stay sharp.

If it doesn’t touch the cannabis plant, we don’t touch it either.

3. We Respect Psilocybin — But Our Roots Are in Cannabis.

Let’s be clear: we respect psilocybin and the therapeutic potential of β-Carbolines, tryptamines, and entheogenic fungi. We recognize its deep cultural, clinical, and ancestral significance. But we didn’t grow out of that world.

Our origin story is medical cannabis. We stood with operators when access was a risk, when banks wouldn’t call back, when 280E crushed margins and CDTFA letters landed hard. That’s where we come from — and that’s where we continue to fight.

From a public policy and advocacy standpoint, we also believe cannabis deserves its own lane. When lumped together with psychedelics under one reform umbrella, cannabis reform risks losing focus, political traction, and public clarity.

Cannabis has come too far — and still has too far to go.

🔍 Need a CFO Who Knows Cannabis Inside and Out?

If you’re a licensed cannabis or hemp business owner, investor, or compliance pro — we’re ready to talk:

  • 280E mitigation strategies

  • Inventory and cost accounting

  • Financial modeling and cash flow

  • Licensing and application financials

  • CDTFA and IRS audit defense

📬 Connect with us at CannabisCPA.tax
Let’s grow your cannabis business with confidence, clarity, and compliance.